



**Dr. Reddy's Laboratories Ltd.**  
8-2-337, Road No. 3, Banjara Hills  
Hyderabad – 500 034, Telangana, India  
CIN: L85195TG1984PLC004507  
Tel: + 91 40 4900 2900  
Fax: + 91 40 4900 2999  
Email: [mail@drreddys.com](mailto:mail@drreddys.com)  
Web: [www.drreddys.com](http://www.drreddys.com)

July 22, 2025

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)  
BSE Limited (Scrip Code: 500124)

Dear Sir/Madam,

**Sub: Update on our intimation dated July 21, 2025 - Disclosure under Regulation 30 of the SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

Further to our intimation dated May 17, 2025, and July 21, 2025, wherein we had informed regarding the GMP inspection conducted by the United States Food & Drug Administration (USFDA) at our API facility in Middleburgh, New York, and that the Company has received the Establishment Inspection Report (EIR). The USFDA has classified the inspection outcome as 'Voluntary Action Indicated (VAI)' and concluded that the inspection is officially closed under 21 CFR 20.64(d)(3).

In this regard, please further note that the Company has received Establishment Inspection Report (EIR) on July 21, 2025.

This is for your information and record.

Thanking you.

Yours faithfully,  
For **Dr. Reddy's Laboratories Limited**

**K Randhir Singh**  
*Company Secretary, Compliance Officer & Head-CSR*